Article
Miltefosine enhances infectivity of miltefosine-resistant <i>Leishmania infantum</i> by attenuating innate immune recognition
2021-02-25
Abstract excerpt
Miltefosine (MIL) is currently the only oral drug available to treat visceral leishmaniasis but its use as first-line monotherapy has been compromised by an increasing treatment failure. Despite the scarce number of resistant clinical isolates, MIL-resistance by mutations in a single aminophospholipid transporter gene can easily be selected in a laboratory environment. These mutations result in a reduced survival...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3d23b554-6847-56d7-9e3b-deb87991cd71
- DOI
- 10.1101/2021.02.22.432409
